Business Context and Reporting Period
Company: NANOVIRICIDES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 8, 2012
Event: Closing of a securities offering pursuant to a Securities Purchase Agreement dated November 1, 2011.
Key Financial Metrics
- Gross Proceeds: $2,500,000 raised from the sale of 250,000 shares of Series B Convertible Preferred Stock.
- Purchase Price: $10.00 per share of Series B Preferred Stock.
- Estimated Offering Expenses: Approximately $180,000 (includes placement agent and attorneys' fees).
- Placement Agent Fee: 6% of the gross purchase price paid to Midtown Partners & Co., LLC.
- Initial Conversion: 40,000 shares of Series B Preferred Stock converted to Common Stock on February 8, 2012, at a conversion price of $0.55777 per share.
- Dividend Rate: 10% per annum, payable in cash or Common Stock at a 15% discount to the 10-day VWAP.
Material Changes and Transaction Details
The company completed a capital raise involving Seaside 88, LP. The transaction involves a convertible preferred stock structure with specific conversion mechanics:
- Conversion Schedule: 40,000 shares convert every 14 days thereafter until fully converted.
- Conversion Formula: Based on the lower of (i) 85% of the 10-day VWAP or (ii) 88% of the prior day's VWAP.
- Conversion Floor: Conversions will not occur if the 20-day VWAP is below $0.20.
- Registration Rights: Conversions are contingent on an effective registration statement; failure to register triggers redemption rights for the investor.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding anticipated subsequent conversions. Management highlights the following risks and contingencies:
- Dilution: Substantial dilution to current stockholders due to the purchase price discount offered to Seaside.
- Market Overhang: Potential market overhang from shares available for sale upon conversion and subsequent resale by Seaside.
- Execution Risk: Uncertainty regarding the ability to satisfy closing conditions on a timely basis.
- Regulatory Dependency: Conversion is dependent on the effectiveness of the registration statement (Form S-3).
Investor Verification Checklist
- Verify the effectiveness of the Form S-3 registration statement (File No. 333-165221) to ensure future conversions can proceed.
- Monitor the daily VWAP of Common Stock to assess the likelihood of the $0.20 conversion floor being breached.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for detailed redemption rights and dividend payment terms.
- Assess the impact of the 15% discount on dividend payments and the 85-88% discount on conversion prices on existing shareholder equity.